---
title: "Biohaven: Pipeline Promise Offset by Cash Constraints and Clinical Uncertainty; Hold Rating Reiterated with Unchanged $10 Price Target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295694374.md"
description: "H.C. Wainwright analyst Douglas Tsao reiterated a Hold rating on Biohaven with an unchanged $10 price target. The decision balances the company's promising pipeline against significant cash constraints and clinical uncertainties. With only two quarters of runway, execution is critical. Key catalysts like opakalim data face interpretive challenges and strong competition, while other assets lack clear differentiation, justifying the neutral stance."
datetime: "2026-08-12T17:15:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295694374.md)
  - [en](https://longbridge.com/en/news/295694374.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295694374.md)
generator: "portal-rs"
---

# Biohaven: Pipeline Promise Offset by Cash Constraints and Clinical Uncertainty; Hold Rating Reiterated with Unchanged $10 Price Target

Douglas Tsao, an analyst from H.C. Wainwright, reiterated the Hold rating on Biohaven Ltd.. The associated price target remains the same with $10.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Douglas Tsao has given his Hold rating due to a combination of factors, balancing Biohaven’s promising pipeline with meaningful financial and clinical risks. The company’s cash position, at roughly two quarters of runway, leaves limited flexibility, making execution on upcoming studies critical and reducing room for setbacks despite multiple programs in development.

Tsao also views the forthcoming opakalim data in focal epilepsy as a key but uncertain catalyst, given interpretive challenges around existing open-label results and the strong competitive benchmark set by Xenon’s azetukalner. Additional assets such as taldefgrobep in obesity and BHV-1300 in Graves Disease face questions around differentiation and ultimate commercial impact, leading him to maintain a neutral stance and keep the price target unchanged at $10.

### Related Stocks

- [BHVN.US](https://longbridge.com/en/quote/BHVN.US.md)
- [XENE.US](https://longbridge.com/en/quote/XENE.US.md)

## Related News & Research

- [Is Biohaven (BHVN) Undervalued Following Its Latest Earnings Loss Improvement?](https://longbridge.com/en/news/296708698.md)
- [Biohaven Ltd. $BHVN Shares Bought by Quantinno Capital Management LP](https://longbridge.com/en/news/296018014.md)
- [Rhythm Pharma says Japan regulator approves IMCIVREE for acquired hypothalamic obesity](https://longbridge.com/en/news/296784537.md)
- [Eli Lilly and Novo Nordisk Can't Treat This Form of Obesity. Billionaire Stanley Druckenmiller Is Betting Rhythm Pharmaceuticals Can](https://longbridge.com/en/news/296711443.md)
- [Stockholder Alert: Robbins LLP Informs Investors of the Fractyl Health, Inc. Class Action](https://longbridge.com/en/news/296661054.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**